T
TRYP
vs
S
S&P TSX Composite Index (Canada)
Over the past 12 months, TRYP has underperformed S&P TSX Composite Index (Canada), delivering a return of 0% compared to the S&P TSX Composite Index (Canada)'s +27% growth.
Stocks Performance
TRYP vs S&P TSX Composite Index (Canada)
Performance Gap
TRYP vs S&P TSX Composite Index (Canada)
Performance By Year
TRYP vs S&P TSX Composite Index (Canada)
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
TRYP Therapeutics Inc
Glance View
Tryp Therapeutics, Inc. is a pharmaceutical company, which engages in identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs. The company is headquartered in Kelowna, British Columbia. The company went IPO on 2020-12-18. The firm is focused on developing psilocybin-related molecules, including TRP-8803, for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. The Company’s lead development program, Psilocybin-For-Neuropsychiatric Disorders (PFN) program, is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. The primary indications for its PFN are in the areas of chronic pain, including fibromyalgia, phantom limb pain and complex regional pain syndrome, and eating disorders, including binge eating and hypothalamic obesity. The firm's product pipeline includes TRP-8802 and TRP-8803. TRP-8803 uses a formulation and route of administration to improve the patient experience. The firm is also engaged in developing a formulation of razoxane for the treatment of soft tissue sarcomas.
